Close Menu

NEW YORK ─ Marlborough, Massachusetts-based Hologic announced after the close of the market on Tuesday that it will acquire molecular diagnostics firm Biotheranostics for approximately $230 million.

San Diego-based Biotheranostics develops and provides diagnostic, prognostic, and predictive tests that support physicians in the treatment of cancer patients.

The company offers testing services through a CLIA-certified, CAP-accredited laboratory that is directly licensed or otherwise authorized to perform testing in all 50 US states, Hologic said.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

May
26
Sponsored by
Lexogen

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.

Jun
08
Sponsored by
Qiagen

Cancer is a complex and heterogeneous disease requiring patient-specific molecular analysis to support treatment decisions.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.